2013 Fiscal Year Final Research Report
Development of treatment for bacterial translocation in rat's biliary atresia model.
| Project/Area Number |
24890151
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
YADA Keigo 徳島大学, 大学病院, 医員 (00633893)
|
|---|
| Research Collaborator |
SHIMADA Mitsuo 徳島大学, 大学院ヘルスバイオサイエンス 研究部, 教授 (10216070)
ISHIBASHI Hiroki 徳島大学, 病院, 講師 (20314867)
MORI Hiroki 徳島大学, 病院, 助教 (70448330)
|
|---|
| Project Period (FY) |
2012-08-31 – 2014-03-31
|
| Keywords | 閉塞性黄疸 / 胆道閉鎖症 / バクテリアル・トランスロケーション / 肝線維化 / 大建中湯 |
|---|
| Research Abstract |
Male Wistar rats were divided into the three groups:Group1,control;Group2, receiving BDL only;Group3,receiving BDL and oral administration of TU-100.In Gr.2 and Gr.3,rats were sacrificed at 3,7 or 14 days after BDL. As a result:(1) Gr.3 had lower GPT on POD3 and lower serum HA on POD14 than Gr.1 and Gr.2,respectively(p<0.05).(2)BT was observed 0% in Gr.1 and 100% in Gr.2 on POD3,7 and 14. In contrast,it was detected 100% on POD3,20% on POD7, and 0% on POD14 in Gr.3. (3)Number and height of villus in Gr.3 were preserved compared to Gr.2,in time dependent manner(on POD 7,14, p<0.01).(4)Area of liver fibrosis and positive alpha-SMA area in Gr.3 were smaller than those in Gr.2(p<0.05).(5)In vitro experiment using HSCs isolated from BDL rats showed less expression of alpha SMA, timp1 and colI alpha 1 in TU-100 administration group. In conclusion,TU-100 may improve liver fibrosis by suppressing the activated HSCs and maintaining intestinal integrity in patients with biliary atresia.
|
-
-
-
[Journal Article] Effects of Bevacizumab on liver damage after massive hepatectomy in rats2014
Author(s)
Mori H, Ishibashi H, Shimada M, Utsunomiya T, Asanoma M, Yamada S, Saito Y, Yada K, Iwahashi S, Ikemoto T, Imura S, Morine Y
-
Journal Title
Hepatogastroenterology
Volume: (in press)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
